Clinical trial
Melphalan With or Without Tumor Necrosis Factor in Treating Patients With…
NCT00003789 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00003789 |
|---|---|
| Title | Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg |
| Official title | A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion and Melphalan With and Without Tumor Necrosis Factor in Patients With Localized Advanced Extremity Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage III Melanoma |
| Intervention type | Biological, Drug, Other |
| Interventions | isolated limb perfusion, melphalan, recombinant tumor necrosis factor family protein, pharmacological study, laboratory biomarker analysis |
| Enrollment | 216 |
| Start date | Mar 1, 1999 |
| Primary completion | Jan 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: